Iron-induced damage in cardiomyopathy: Oxidative-dependent and independent mechanisms

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Gammella, Elena ^a   Recalcati, Stefania ^a   Rybinska, Ilona ^a   Buratti, Paolo ^a   Cairo, Gaetano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLOGY; CELL DEATH; HEART; IMAGING TECHNIQUES;

HIGH INCIDENCE; INFLAMMATORY MEDIATORS; INITIATING EVENTS; IRON ACCUMULATION; PATHOGENIC MECHANISMS; REACTIVE OXYGEN SPECIES; SUBCELLULAR ORGANELLES; THERAPEUTIC STRATEGY;

IRON;

DOXORUBICIN; IRON; IRON CHELATING AGENT; DEFEROXAMINE; IRON REGULATORY FACTOR; REACTIVE OXYGEN METABOLITE; SIDEROPHORE;

APOPTOSIS; BETA THALASSEMIA; CARDIAC IMAGING; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CELL DAMAGE; CELL ORGANELLE; CELLULAR DISTRIBUTION; CONGESTIVE HEART FAILURE; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FIBROSIS; HEART DISEASE; HEART FAILURE; HEART INJURY; HEART MUSCLE CELL; HEART PROTECTION; HEME SYNTHESIS; HEMOCHROMATOSIS; HEMOSIDEROSIS; HUMAN; IRON BALANCE; IRON OVERLOAD; IRON STORAGE; IRON TRANSPORT; NONHUMAN; OXIDATIVE STRESS; REPERFUSION INJURY; RETICULOENDOTHELIAL SYSTEM; REVIEW; ANIMAL; CARDIOMYOPATHIES; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ANIMALS; CARDIOMYOPATHIES; DEFEROXAMINE; DISEASE MODELS, ANIMAL; HUMANS; IRON; IRON OVERLOAD; IRON-REGULATORY PROTEINS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIDEROPHORES;

EID: 84927154683     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/230182     Document Type: Review

References (97)

1. K. Pantopoulos, S. K. Porwal, A. Tartakoff, and L. Devireddy, "Mechanisms of mammalian iron homeostasis, " Biochemistry, vol. 51, no. 29, pp. 5705-5724, 2012.
2. J. A. Imlay, "The mismetallation of enzymes during oxidative stress, "The Journal of Biological Chemistry, vol. 289, no. 41, pp. 28121-28128, 2014.
3. M. W. Hentze, M. U. Muckenthaler, B. Galy, andC. Camaschella, "Two to tango: regulation ofmammalian ironmetabolism, " Cell, vol. 142, no. 1, pp. 24-38, 2010.
4. M. D. Garrick, "Human iron transporters, " Genes & Nutrition, vol. 6, no. 1, pp. 45-54, 2011.
5. D. Meynard, J. L. Babitt, and H. Y. Lin, "The liver: conductor of systemic iron balance, " Blood, vol. 123, no. 2, pp. 168-176, 2014.
6. T. Ganz and E. Nemeth, "Hepcidin and iron homeostasis, " Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1823, no. 9, pp. 1434-1443, 2012.
7. S. Recalcati, G. Minotti, andG. Cairo, "Iron regulatory proteins: from molecular mechanisms to drug development, " Antioxidants and Redox Signaling, vol. 13, no. 10, pp. 1593-1616, 2010.
8. L. R. Zacharski, D. L. Ornstein, S. Woloshin, and L. M. Schwartz, "Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data, " American Heart Journal, vol. 140, no. 1, pp. 98-104, 2000.
9. S. Toyokuni, "Iron as a target of chemoprevention for longevity in humans, " Free Radical Research, vol. 45, no. 8, pp. 906-917, 2011.
10. J. Xu, E. Marzetti, A. Y. Seo, J. -S. Kim, T. A. Prolla, and C. Leeuwenburgh, "The emerging role of iron dyshomeostasis in the mitochondrial decay of aging, " Mechanisms of Ageing and Development, vol. 131, no. 7-8, pp. 487-493, 2010.
11. E. Mocchegiani, L. Costarelli, R. Giacconi, F. Piacenza, A. Basso, and M. Malavolta, "Micronutrient (Zn, Cu, Fe)-gene interactions in ageing and inflammatory age-related diseases: implications for treatments, " Ageing Research Reviews, vol. 11, no. 2, pp. 297-319, 2012.
12. Y. -R. Chen and J. L. Zweier, "Cardiacmitochondria and reactive oxygen species generation, " Circulation Research, vol. 114, no. 3, pp. 524-537, 2014.
13. S. Lakhal-Littleton, M. Wolna, C. A. Carr et al., "Cardiac ferroportin regulates cellular iron homeostasis and is important for cardiac function, " Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 10, pp. 3164-3169, 2015.
14. J. H. Doroshow, G. Y. Locker, and C. E. Myers, "Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin, " Journal of Clinical Investigation, vol. 65, no. 1, pp. 128-135, 1980.
15. P. Arosio and S. Levi, "Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage, " Biochimica et Biophysica Acta-General Subjects, vol. 1800, no. 8, pp. 783-792, 2010.
16. G. Cairo, E. Rappocciolo, L. Tacchini, and L. Schiaffonati, "Expression of the genes for the ferritin H and L subunits in rat liver and heart. Evidence for tissue-specific regulations at preand post-translational levels, " Biochemical Journal, vol. 275, part 3, pp. 813-816, 1991.
17. M. Chevion, S. Leibowitz, N. N. Aye et al., "Heart protection by ischemic preconditioning: a novel pathway initiated by iron and mediated by ferritin, " Journal of Molecular and Cellular Cardiology, vol. 45, no. 6, pp. 839-845, 2008.
18. G. Cairo, L. Tacchini, G. Pogliaghi, E. Anzon, A. Tomasi, and A. Bernelli-Zazzera, "Induction of ferritin synthesis by oxidative stress: transcriptional and post-transcriptional regulation by expansion of the 'free' iron pool, " The Journal of Biological Chemistry, vol. 270, no. 2, pp. 700-703, 1995.
19. L. Tacchini, S. Recalcati, A. Bernelli-Zazzera, and G. Cairo, "Induction of ferritin synthesis in ischemic-reperfused rat liver: analysis of the molecular mechanisms, " Gastroenterology, vol. 113, no. 3, pp. 946-953, 1997.
20. B. E. Bulvik, E. Berenshtein, E. G. Meyron-Holtz, A. M. Konijn, andM. Chevion, "Cardiac protection by preconditioning is generated via an iron-signal created by proteasomal degradation of iron proteins, " PLoS ONE, vol. 7, no. 11, Article ID e48947, 2012.
21. D. M. Frazer and G. J. Anderson, "The regulation of iron transport, " BioFactors, vol. 40, no. 2, pp. 206-214, 2014.
22. Z. I. Cabantchik, "Labile iron in cells and body fluids: physiology, pathology, and pharmacology, " Frontiers in Pharmacology, vol. 5, article 45, 2014.
23. R. C. Hider, "Nature of nontransferrin-bound iron, " European Journal of Clinical Investigation, vol. 32, no. 1, pp. 50-54, 2002.
24. J. P. Liuzzi, F. Aydemir, H. Nam, M. D. Knutson, and R. J. Cousins, "Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 37, pp. 13612-13617, 2006.
25. S. Ludwiczek, I. Theurl, M. U. Muckenthaler et al., "Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1, " Nature Medicine, vol. 13, no. 4, pp. 448-454, 2007.
26. G. Y. Oudit, H. Sun, M. G. Trivieri et al., "L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy, " Nature Medicine, vol. 9, no. 9, pp. 1187-1194, 2003.
27. C. J. Murphy and G. Y. Oudit, "Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment, " Journal of Cardiac Failure, vol. 16, no. 11, pp. 888-900, 2010.
28. P. Brissot, M. Ropert, C. Le Lan, and O. Loréal, "Non-transferrin bound iron: a key role in iron overload and iron toxicity, " Biochimica et Biophysica Acta-General Subjects, vol. 1820, no. 3, pp. 403-410, 2012.
29. R. A. Rose, M. Sellan, J. A. Simpson et al., "Iron overload decreases Cav1. 3-dependent L-type Ca2+ currents leading to bradycardia, altered electrical conduction, and atrial fibrillation, " Circulation: Arrhythmia and Electrophysiology, vol. 4, no. 5, pp. 733-742, 2011.
30. C. -F. Cheng and W. -S. Lian, "Prooxidant mechanisms in iron overload cardiomyopathy, " BioMed Research International, vol. 2013, Article ID 740573, 8 pages, 2013.
31. G. Xu, J. Ahn, S. Chang et al., "Lipocalin-2 induces cardiomyocyte apoptosis by increasing intracellular iron accumulation, " The Journal of Biological Chemistry, vol. 287, no. 7, pp. 4808-4817, 2012.
32. C. J. Brewer, R. I. Wood, and J. C. Wood, "mRNA regulation of cardiac iron transporters and ferritin subunits in amousemodel of iron overload, " Experimental Hematology, vol. 42, no. 12, pp. 1059-1067, 2014.
33. L. Kautz and E. Nemeth, "Molecular liaisons between erythropoiesis and iron metabolism, " Blood, vol. 124, no. 4, pp. 479-482, 2014.
34. L. J. Noetzli, S. M. Carson, A. S. Nord, T. D. Coates, and J. C. Wood, "Longitudinal analysis of heart and liver iron in thalassemia major, " Blood, vol. 112, no. 7, pp. 2973-2978, 2008.
35. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni, "Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity, " Pharmacological Reviews, vol. 56, no. 2, pp. 185-229, 2004.
36. C. J. Miranda, H. Makui, R. J. Soares et al., "Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin, " Blood, vol. 102, no. 7, pp. 2574-2580, 2003.
37. S. E. Lipshultz, S. R. Lipsitz, J. L. Kutok et al., "Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia, " Cancer, vol. 119, no. 19, pp. 3555-3562, 2013.
38. Y. Octavia, C. G. Tocchetti, K. L. Gabrielson, S. Janssens, H. J. Crijns, and A. L. Moens, "Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies, " Journal of Molecular and Cellular Cardiology, vol. 52, no. 6, pp. 1213-1225, 2012.
39. M. Stěrba, O. Popelová, A. Vávrová et al., "Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection, " Antioxidants and Redox Signaling, vol. 18, no. 8, pp. 899-929, 2013.
40. C. E. Thomas and S. D. Aust, "Reductive release of iron from ferritin by cation free radicals of paraquat and other bipyridyls, " The Journal of Biological Chemistry, vol. 261, no. 28, pp. 13064-13070, 1986.
41. E. Gammella, F. Maccarinelli, P. Buratti, S. Recalcati, and G. Cairo, "The role of iron in anthracycline cardiotoxicity, " Frontiers in Pharmacology, vol. 5, article 25, 2014.
42. Y. Ichikawa, M. Ghanefar, M. Bayeva et al., "Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation, " Journal of Clinical Investigation, vol. 124, no. 2, pp. 617-630, 2014.
43. F. Maccarinelli, E. Gammella, M. Asperti et al., "Mice lacking mitochondrial ferritin are more sensitive to doxorubicinmediated cardiotoxicity, " Journal ofMolecularMedicine, vol. 92, no. 8, pp. 859-869, 2014.
44. R. D. Spagnuolo, S. Recalcati, L. Tacchini, and G. Cairo, "Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity, " British Journal of Pharmacology, vol. 163, no. 2, pp. 299-312, 2011.
45. C. Henninger, S. Huelsenbeck, P. Wenzel et al., "Chronic heart damage following doxorubicin treatment is alleviated by lovastatin, " Pharmacological Research, vol. 91, pp. 47-56, 2015.
46. L. Mascitelli and M. R. Goldstein, "Might the beneficial effects of statin drugs be related to their action on iron metabolism?" Quarterly Journal of Medicine, vol. 105, no. 12, pp. 1225-1229, 2012.
47. Z. I. Cabantchik, A. Munnich, M. B. Youdim, and D. Devos, "Regional siderosis: a new challenge for iron chelation therapy, " Frontiers in Pharmacology, vol. 4, article 167, 2013.
48. J. W. Rensvold, S. -E. Ong, A. Jeevananthan, S. A. Carr, V. K. Mootha, and D. J. Pagliarini, "Complementary RNA and protein profiling identifies iron as a key regulator of mitochondrial biogenesis, " Cell Reports, vol. 3, no. 1, pp. 237-245, 2013.
49. M. Shvartsman, R. Kikkeri, A. Shanzer, and Z. I. Cabantchik, "Non-transferrin-bound iron reaches mitochondria by a chelator-inaccessible mechanism: biological and clinical implications, " American Journal of Physiology-Cell Physiology, vol. 293, no. 4, pp. C1383-C1394, 2007.
50. X. Gao, M. Qian, J. L. Campian et al., "Mitochondrial dysfunction may explain the cardiomyopathy of chronic iron overload, " Free Radical Biology and Medicine, vol. 49, no. 3, pp. 401-407, 2010.
51. R. M. Payne, "The heart in friedreich's ataxia: basic findings and clinical implications, " Progress in Pediatric Cardiology, vol. 31, no. 2, pp. 103-109, 2011.
52. A. Martelli and H. Puccio, "Dysregulation of cellular iron metabolism in Friedreich ataxia: from primary iron-sulfur cluster deficit tomitochondrial iron accumulation, " Frontiers in Pharmacology, vol. 5, article 130, 2014.
53. L. K. Beilschmidt and H. M. Puccio, "Mammalian Fe-S cluster biogenesis and its implication in disease, " Biochimie, vol. 100, no. 5, pp. 48-60, 2014.
54. Y. Ichikawa, M. Ghanefar, M. Bayeva et al., "Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation, " The Journal of Clinical Investigation, vol. 124, no. 2, pp. 617-630, 2014.
55. S. Tamir, M. L. Paddock, M. Darash-Yahana-Baram et al., "Structure-function analysis of NEET proteins uncovers their role as key regulators of iron and ROS homeostasis in health and disease, " Biochimica et Biophysica Acta-Molecular Cell Research, 2014.
56. Y. -S. Sohn, W. Breuer, A. Munnich, and Z. I. Cabantchik, "Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications, " Blood, vol. 111, no. 3, pp. 1690-1699, 2008.
57. G. Y. Oudit, M. G. Trivieri, N. Khaper et al., "Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload murine model, " Circulation, vol. 109, no. 15, pp. 1877-1885, 2004.
58. Y. Wang, M. Wu, R. Al-Rousan et al., "Iron-induced cardiac damage: role of apoptosis and deferasirox intervention, " Journal of Pharmacology and ExperimentalTherapeutics, vol. 336, no. 1, pp. 56-63, 2011.
59. H. Lin, H. -F. Li, W. -S. Lian et al., "Thromboxane A2 mediates iron-overload cardiomyopathy in mice through calcineurinnuclear factor of activated t cells signaling pathway, " Circulation Journal, vol. 77, no. 10, pp. 2586-2595, 2013.
60. L. Kiczak, A. Tomaszek, J. Bania et al., "Matrix metalloproteinase 9/neutrophil gelatinase associated lipocalin/tissue inhibitor of metalloproteinasess type 1 complexes are localized within cardiomyocytes and serve as a reservoir of active metalloproteinase in porcine female myocardium, " Journal of Physiology and Pharmacology, vol. 65, no. 3, pp. 365-375, 2014.
61. S. N. Moon, J. W. Han, H. S. Hwang et al., "Establishment of secondary iron overloaded mouse model: evaluation of cardiac function and analysis according to iron concentration, " Pediatric Cardiology, vol. 32, no. 7, pp. 947-952, 2011.
62. M. Otto-Duessel, C. Brewer, I. Gonzalez, H. Nick, and J. C. Wood, "Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload, " Acta Haematologica, vol. 120, no. 2, pp. 123-128, 2008.
63. C. Sanyear, P. Butthep, R. Nithipongvanich et al., "Cardiomyocyte ultrastructural damage in β-thalassaemic mice, " International Journal of Experimental Pathology, vol. 94, no. 5, pp. 336-342, 2013.
64. V. N. Subramaniam, C. J. McDonald, L. Ostini et al., "Hepatic iron deposition does not predict extrahepatic iron loading in mouse models of hereditary hemochromatosis, " The American Journal of Pathology, vol. 181, no. 4, pp. 1173-1179, 2012.
65. C. Brewer, M. Otto-Duessel, R. I. Wood, and J. C. Wood, "Sex differences and steroid modulation of cardiac iron in a mouse model of iron overload, " Translational Research, vol. 163, no. 2, pp. 151-159, 2014.
66. E. Ramos, P. Ruchala, J. B. Goodnough et al., "Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis, " Blood, vol. 120, no. 18, pp. 3829-3836, 2012.
67. R. E. Fleming and P. Ponka, "Mechanisms of disease: iron overload in human disease, " The New England Journal of Medicine, vol. 366, no. 4, pp. 348-359, 2012.
68. A. Cohen-Solal, C. Leclercq, G. Deray et al., "Iron deficiency: an emerging therapeutic target in heart failure, " Heart, vol. 100, no. 18, pp. 1414-1420, 2014.
69. V. Pullarkat, "Iron toxicity in hematopoietic stem cell transplantation: strike while the iron is labile, " Acta Haematologica, vol. 131, no. 4, pp. 220-221, 2014.
70. A. Pietrangelo, "Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment, " Gastroenterology, vol. 139, no. 2, pp. 393-408, 2010.
71. M. B. Leon, J. S. Borer, S. L. Bacharach et al., "Detection of early cardiac dysfunction in patients with severe betathalassemia and chronic iron overload, " The New England Journal of Medicine, vol. 301, no. 21, pp. 1143-1148, 1979.
72. C. Camaschella, A. Roetto, and M. de Gobbi, "Juvenile hemochromatosis, " Seminars in Hematology, vol. 39, no. 4, pp. 242-248, 2002.
73. V. Gulati, P. Harikrishnan, C. Palaniswamy, W. S. Aronow, D. Jain, andW. H. Frishman, "Cardiac involvement in hemochromatosis, " Cardiology in Review, vol. 22, no. 2, pp. 56-68, 2014.
74. G. Sebastiani and K. Pantopoulos, "Disorders associated with systemic or local iron overload: from pathophysiology to clinical practice, " Metallomics, vol. 3, no. 10, pp. 971-986, 2011.
75. T. D. Coates, "Physiology and pathophysiology of iron in hemoglobin-associated diseases, " Free Radical Biology and Medicine, vol. 72, pp. 23-40, 2014.
76. V. Pullarkat, "Objectives of iron chelation therapy in myelodysplastic syndromes:more thanmeets the eye?" Blood, vol. 114, no. 26, pp. 5251-5255, 2009.
77. J. C. Wood, "History and current impact of cardiac magnetic resonance imaging on the management of iron overload, " Circulation, vol. 120, no. 20, pp. 1937-1939, 2009.
78. L. J. Anderson, S. Holden, B. Davis et al., "Cardiovascular T2-star (T2∗) magnetic resonance for the early diagnosis of myocardial iron overload, " European Heart Journal, vol. 22, no. 23, pp. 2171-2179, 2001.
79. F. Moussavi, M.A. Ghasabeh, S. Roodpeyma et al., "Optimal method for early detection of cardiac disorders in thalassemia major patients: magnetic resonance imaging or echocardiography?" Blood Research, vol. 49, no. 3, pp. 182-186, 2014.
80. A. J. Baksi and D. J. Pennell, "Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major, " Frontiers in Pharmacology, vol. 5, article 217, 2014.
81. G. M. Brittenham, "Iron-chelating therapy for transfusional iron overload, " The New England Journal of Medicine, vol. 364, no. 2, pp. 146-156, 2011.
82. D. J. Pennell, V. Berdoukas, M. Karagiorga et al., "Randomized controlled trial of deferiprone or deferoxamine in betathalassemia major patients with asymptomatic myocardial siderosis, " Blood, vol. 107, no. 9, pp. 3738-3744, 2006.
83. A. Pepe, A. Meloni, M. Capra et al., "Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging, " Haematologica, vol. 96, no. 1, pp. 41-47, 2011.
84. S. A. Fisher, S. J. Brunskill, C. Doree, S. Gooding, O. Chowdhury, and D. J. Roberts, "Desferrioxamine mesylate for managing transfusional iron overload in people with transfusiondependent thalassaemia, " The Cochrane Database of Systematic Reviews, vol. 8, Article IDCD004450, 2013.
85. O. Shalev, T. Repka, A. Goldfarb et al., "Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo, " Blood, vol. 86, no. 5, pp. 2008-2013, 1995.
86. J. L. Kwiatkowski, "Real-world use of iron chelators, " Hematology/the Education Program of the American Society of Hematology, vol. 2011, pp. 451-458, 2011.
87. A. Piga, S. Fracchia, M. E. Lai et al., "Deferasirox effect on renal haemodynamic parameters in patients with transfusiondependent β thalassaemia, " British Journal of Haematology, vol. 168, no. 6, pp. 882-890, 2015.
88. C. N. Kontoghiorghe, A. Kolnagou, and G. J. Kontoghiorghes, "Antioxidant targeting by deferiprone in diseases related to oxidative damage, " Frontiers in Bioscience, vol. 19, no. 6, pp. 862-885, 2014.
89. T. Zhou, Y. Ma, X. Kong, and R. C. Hider, "Design of iron chelators with therapeutic application, " Dalton Transactions, vol. 41, no. 21, pp. 6371-6389, 2012.
90. L. D. Devanur, R. W. Evans, P. J. Evans, and R. C. Hider, "Chelator-facilitated removal of iron fromtransferrin: relevance to combined chelation therapy, " Biochemical Journal, vol. 409, no. 2, pp. 439-447, 2008.
91. M.A. Tanner, R. Galanello, C. Dessi et al., "A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone onmyocardial iron in thalassemiamajor using cardiovascular magnetic resonance, " Circulation, vol. 115, no. 14, pp. 1876-1884, 2007.
92. R. G. Tsushima, A. D. Wickenden, R. A. Bouchard, G. Y. Oudit, P. P. Liu, and P. H. Backx, "Modulation of iron uptake in heart by L-type Ca2+ channel modifiers: possible implications in iron overload, " Circulation Research, vol. 84, no. 11, pp. 1302-1309, 1999.
93. G. Y. Oudit, M. G. Trivieri, N. Khaper, P. P. Liu, and P. H. Backx, "Role of L-typeCa2+ channels in iron transport and ironoverload cardiomyopathy, " Journal of Molecular Medicine, vol. 84, no. 5, pp. 349-364, 2006.
94. S. Kumfu, S. Chattipakorn, K. Chinda, S. Fucharoen, and N. Chattipakorn, "T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice, " European Journal of Haematology, vol. 88, no. 6, pp. 535-548, 2012.
95. J. L. Fernandes, E. F. Sampaio, K. Fertrin et al., "Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial, " The American Journal of Medicine, vol. 126, no. 9, pp. 834-837, 2013.
96. A. Shakoor, M. Zahoor, A. Sadaf et al., "Effect of L-type calcium channel blocker (amlodipine) onmyocardial iron deposition in patients with thalassaemia withmoderate-to-severemyocardial iron deposition: protocol for a randomised, controlled trial, " BMJ Open, vol. 4, no. 12, Article IDe005360, 2014.
97. H. Jansová, M. Macháček, Q. Wang et al., "Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury, " Free Radical Biology and Medicine, vol. 74, pp. 210-221, 2014.